Topiramate in the treatment of partial and generalized epilepsy

Edward FaughtDepartment of Neurology, University of Alabama School of Medicine, Birmingham, Alabama, USAAbstract: Topiramate (TPM) is a widely-used drug for the treatment of epilepsy. It is useful for several types of partial-onset and generalized-onset seizures, and is therefore considered a broad-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Edward Faught
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c3a7c401cf224b54be310d7187b9b625
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3a7c401cf224b54be310d7187b9b625
record_format	dspace
spelling	oai:doaj.org-article:c3a7c401cf224b54be310d7187b9b6252021-12-02T03:31:34ZTopiramate in the treatment of partial and generalized epilepsy1176-63281178-2021https://doaj.org/article/c3a7c401cf224b54be310d7187b9b6252007-01-01T00:00:00Zhttp://www.dovepress.com/topiramate-in-the-treatment-of-partial-and-generalized-epilepsy-a959https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Edward FaughtDepartment of Neurology, University of Alabama School of Medicine, Birmingham, Alabama, USAAbstract: Topiramate (TPM) is a widely-used drug for the treatment of epilepsy. It is useful for several types of partial-onset and generalized-onset seizures, and is therefore considered a broad-spectrum agent. It is also effective as a prophylactic against migraine headaches. TPM was first approved for prescription use in 1996. In various countries it is now approved for adjunctive and monotherapy of partial-onset seizures and for therapy of generalized tonic-clonic seizures of nonfocal origin, for children and adults. For initial monotherapy of new-onset seizures, a target dose of 100 mg/day for adults is recommended. Adjunctive use with enzyme-inducing drugs and use for refractory seizures requires higher dosages, though the optimum dose for most patients does not exceed 400 mg/day. Excretion is primarily renal and TPM is not a significant hepatic enzyme inducer. Although it is usually safe and well-tolerated, adverse effects limit use in about 25% of patients. The most salient of these is cognitive dysfunction, especially problems with expressive speech and verbal memory. Weight loss, renal stones, paresthesias and other central nervous system side effects may occur. Tolerability is improved by low initial doses and slow titration to effect.Keywords: epilepsy, seizures, antiepileptic drugs, topiramate Edward FaughtDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 811-821 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Edward Faught Topiramate in the treatment of partial and generalized epilepsy
description	Edward FaughtDepartment of Neurology, University of Alabama School of Medicine, Birmingham, Alabama, USAAbstract: Topiramate (TPM) is a widely-used drug for the treatment of epilepsy. It is useful for several types of partial-onset and generalized-onset seizures, and is therefore considered a broad-spectrum agent. It is also effective as a prophylactic against migraine headaches. TPM was first approved for prescription use in 1996. In various countries it is now approved for adjunctive and monotherapy of partial-onset seizures and for therapy of generalized tonic-clonic seizures of nonfocal origin, for children and adults. For initial monotherapy of new-onset seizures, a target dose of 100 mg/day for adults is recommended. Adjunctive use with enzyme-inducing drugs and use for refractory seizures requires higher dosages, though the optimum dose for most patients does not exceed 400 mg/day. Excretion is primarily renal and TPM is not a significant hepatic enzyme inducer. Although it is usually safe and well-tolerated, adverse effects limit use in about 25% of patients. The most salient of these is cognitive dysfunction, especially problems with expressive speech and verbal memory. Weight loss, renal stones, paresthesias and other central nervous system side effects may occur. Tolerability is improved by low initial doses and slow titration to effect.Keywords: epilepsy, seizures, antiepileptic drugs, topiramate
format	article
author	Edward Faught
author_facet	Edward Faught
author_sort	Edward Faught
title	Topiramate in the treatment of partial and generalized epilepsy
title_short	Topiramate in the treatment of partial and generalized epilepsy
title_full	Topiramate in the treatment of partial and generalized epilepsy
title_fullStr	Topiramate in the treatment of partial and generalized epilepsy
title_full_unstemmed	Topiramate in the treatment of partial and generalized epilepsy
title_sort	topiramate in the treatment of partial and generalized epilepsy
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/c3a7c401cf224b54be310d7187b9b625
work_keys_str_mv	AT edwardfaught topiramateinthetreatmentofpartialandgeneralizedepilepsy
_version_	1718401757349937152

Topiramate in the treatment of partial and generalized epilepsy

Ejemplares similares